ESPR Esperion Therapeutics Forecast, Technical & Fundamental Analysis
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs... Show more
ESPR is expected to report earnings to fall 98.60% to 0 cents per share on August 04
Q2'26
Est.
$0.00
Q1'26
Missed
by $0.08
Q4'25
Missed
by $0.07
Q3'25
Missed
by $0.18
Q2'25
Beat
by $0.12
The last earnings report on May 08 showed earnings per share of -10 cents, missing the estimate of -2 cents. With 43.13M shares outstanding, the current market capitalization sits at 819.46M.
A.I.dvisor tells us that ESPR and EVO have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and EVO's prices will move in lockstep.
ESPR in downward trend: price expected to drop as it breaks its higher Bollinger Band on July 08, 2026
ESPR broke above its upper Bollinger Band on July 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 44 similar instances where the stock broke above the upper band. In of the 44 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ESPR moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 06, 2026. You may want to consider a long position or call options on ESPR as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 50-day moving average for ESPR moved above the 200-day moving average on July 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESPR advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 195 cases where ESPR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (39.637). P/E Ratio (0.000) is within average values for comparable stocks, (98.198). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.678). ESPR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.036). P/S Ratio (1.685) is also within normal values, averaging (114.537).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ESPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
